natgillin/translations-raw huggingface dataset:
If you use more Elonva or (rec)FSH than you should If you think you have used more Elonva or (rec)FSH than you should, contact your doctor immediately. 
Če ste uporabili večji odmerek zdravila Elonva ali (rek)FSH, kot bi smeli Če mislite, da ste uporabili več zdravila Elonva ali (rek)FSH, kot bi smeli, se nemudoma posvetujte z zdravnikom.
More than one injection of Elonva within one treatment cycle or too high a dose of Elonva and/or (rec)FSH may increase the risk of OHSS (see OHSS in section 4.4. 
Dajanje več kot ene injekcije zdravila Elonva v posameznem ciklusu zdravljenja ali uporaba prevelikega odmerka zdravila Elonva in/ali (rek)FSH lahko povečata tveganje za OHSS (glejte OHSS v poglavju 4.4).
What Elonva is and what it is used for 
Kaj je zdravilo Elonva in za kaj ga uporabljamo
Early OHSS usually occurs within 10 days after hCG administration and may be associated with an excessive ovarian response to gonadotropin stimulation. 
Zgodnji OHSS običajno nastopi v 10 dneh po prejemu hCG in je lahko združen s čezmernim odzivom jajčnikov na spodbujanje z gonadotropini.
This leaflet was last revised in Month YYYY. 
Navodilo je bilo nazadnje revidirano dne mesec LLLL.
1) and is reached 44 hours (35-57 hours 
1) in je dosežena 44 ur (od 35 do 57 ur 1) po odmerku.
Elonva 150 µg recFSH 300 IU n N % n N % n N % n N % 
(rek)FSH 300 i.e. n N % n N % n N % n N %
The recommended doses of Elonva have only been established in a treatment cycle with a GnRH antagonist that was administered from stimulation day 5 or day 6 onwards (see also sections 4.1, 4.4, and 5.1). 
Priporočeni odmerki zdravila Elonva so bili določeni le v ciklusu zdravljenja z antagonistom GnRH, ki so ga uporabili od 5. ali 6. dne stimulacije naprej (glejte tudi poglavja 4.1, 4.4 in 5.1).
Distribution, metabolism and elimination of corifollitropin alfa are very similar to other gonadotropins, such as FSH, hCG and LH. 
Po porazdelitvi, presnovi in izločanju je korifolitropin alfa zelo podoben drugim gonadotropinom, kot so FSH, hCG in LH.
Women older than 36 years of age who weighed less than 50 kilograms were not studied. 
Uporabe pri ženskah, starejših od 36 let in s telesno maso manj kot 50 kilogramov, niso raziskali.
You should not use Elonva if you are already pregnant, or think that you might be pregnant, or if you are breast-feeding. 
Zdravila Elonva ne smete uporabljati, če ste noseči ali menite, da bi lahko bili noseči, oziroma če dojite.
The incidence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. 
Incidenca kongenitalnih malformacij po asistirani reprodukciji je lahko nekoliko večja kot po spontani zanositvi.
If you forget to use Elonva 
Če ste pozabili uporabiti zdravilo Elonva
Self administration of Elonva should only be performed by women who are well-motivated, adequately trained and with access to expert advice. 
Zdravilo Elonva si smejo same injicirati samo tiste ženske, ki so motivirane in ustrezno usposobljene za to ter imajo dostop do nasveta strokovnjaka.
In each case, these antibodies were non-neutralizing and did not interfere with the response to stimulation or the normal physiologic responses of the Hypothalamic-Pituitary-Ovarian (HPO) axis. 
Pri nobeni ženski ta telesa niso bila nevtralizirajoča in niso vplivala na odziv na stimulacijo ali na normalne fiziološke odzive hipotalamo-hipofizno-ovarijske osi.
Of the 2,511 women treated with Elonva who were evaluated for the formation of post-treatment antibodies, four (0.16%) had evidence of antibody formation, including three who had been exposed once to Elonva and one who had been exposed twice to Elonva. 
Od 2.511 žensk, zdravljenih z zdravilom Elonva, pri katerih so opravili preiskave glede nastajanja protiteles po zdravljenju, so nastajanje protiteles ugotovili pri štirih (0,16 %); tri od njih so bile zdravilu Elonva izpostavljene enkrat, ena pa dvakrat.
Other medicines and Elonva 
Druga zdravila in zdravilo Elonva
Pharmacokinetic parameters of corifollitropin alfa were evaluated after subcutaneous administration in women undergoing a COS treatment cycle. 
Farmakokinetične parametre korifolitropina alfa so ocenili po subkutani uporabi pri ženskah, pri katerih je potekal ciklus zdravljenja COS.
This may be due to cross-reactivity of hCG pregnancy tests with the carboxy-terminal peptide of the beta subunit of Elonva. 
To je lahko zaradi navzkrižne reaktivnosti nekaterih hCG testov nosečnosti s karboksi-terminalnim peptidom beta podenote zdravila Elonva.
Do not throw away an empty or unused syringe via household waste. 
Prazne ali neporabljene injekcijske brizge ne smete odvreči med gospodinjske odpadke.
In particular, women should be evaluated for hypothyroidism, adrenocortical insufficiency, hyperprolactinemia and pituitary or hypothalamic tumours, and appropriate specific treatment given. 
Še posebej je treba te ženske pregledati, da ugotovite, ali imajo hipotireozo, adrenokortikalno insuficienco, hiperprolaktinemijo in tumorje hipofize ali hipotalamusa, ter jim uvesti ustrezno specifično zdravljenje.
Therefore, the use of Elonva is not recommended in combination with a GnRH agonist (see also section 4.2). 
Zato uporaba zdravila Elonva ni priporočljiva v kombinaciji z agonistom GnRH (glejte tudi poglavje 4.2).
Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion. 
Poškodba jajčnikov zaradi zmanjšane prekrvavitve se lahko omeji z zgodnjim odkritjem in takojšnjo detorzijo (odvitjem).
It is not known if treatment with fertility medicines increases the risk of these tumours in infertile women. 
Ni znano, ali zdravljenje z zdravili za plodnost poveča tveganje za nastanek teh tumorjev pri neplodnih ženskah.
No interaction studies with Elonva and other medicines have been performed. 
Študij medsebojnega delovanja zdravila Elonva z drugimi zdravili niso izvedli.
Subcutaneous injection of Elonva may be carried out by the woman herself or her partner, provided that proper instructions are given by the physician. 
Subkutano injiciranje zdravila Elonva lahko izvede ženska sama ali pa ji zdravilo injicira njen partner, pod pogojem, da sta od zdravnika dobila ustrezna navodila.
If you feel dizzy, you should not drive or use machines. 
Če ste omotični, ne upravljajte vozil ali strojev.
Storage by the pharmacist Store in a refrigerator. 
Shranjevanje v lekarni Shranjujte v hladilniku.
Please discuss this with your doctor, before starting treatment, especially if: - you know you already have an increased chance of having a thrombosis - you, or anyone in your immediate family, have ever had a thrombosis - you are severely overweight. 
O tem se morate pogovoriti z zdravnikom še pred začetkom zdravljenja, še posebej: - če veste, da imate že povečano verjetnost za nastanek tromboze, - če ste imeli vi ali kdor koli v vaši ožji družini kadar koli v življenju trombozo, - če imate močno povečano telesno maso.
After absorption into the blood, corifollitropin alfa is distributed mainly to the ovaries and the kidneys. 
Po absorpciji v kri se korifolitropin alfa porazdeli predvsem v jajčnike in ledvice.
A step-by-step “instructions for use” is given at the end of this leaflet. 
Podrobna navodila za dajanje zdravila so podana tudi na koncu teh navodil.
36 years or younger 
36 let ali manj
The table below displays the main adverse reactions in women treated with Elonva in clinical trials and post-marketing surveillance according to system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), and not known (cannot be estimated from available data). 
V spodnji preglednici so podani glavni neželeni učinki pri ženskah, zdravljenih z zdravilom Elonva v kliničnih preskušanjih in v času trženja zdravila, razvrščeni po organskih sistemih in po pogostnosti; zelo pogosti (≥ 1/10), pogosti (od ≥ 1/100 do < 1/10), občasni (od ≥ 1/1.000 do < 1/100), redki (od ≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Corifollitropin alfa exposure after a single subcutaneous injection is 665 hours*ng/mL (AUC, 426-1,037 hours*ng/mL 
Izpostavljenost korifolitropinu alfa po enkratni subkutani injekciji je 665 ur*ng/ml (AUC, 426-1.037 ur*ng/ml
After a single subcutaneous injection of Elonva, the maximum serum concentration of corifollitropin alfa is 4.24 ng/mL (2.49-7.21 ng/mL 
Po enkratni subkutani injekciji zdravila Elonva je največja serumska koncentracija korifolitropina alfa 4,24 ng/ml (2,49-7,21 ng/ml
Injury, poisoning and procedural complications 
Poškodbe, zastrupitve in zapleti postopkov občasni bolečina ob postopku
Do not inject Elonva without talking with your doctor. 
Zdravila Elonva si ne injicirajte, ne da bi se posvetovali z zdravnikom.
The most frequently reported adverse reactions during treatment with Elonva in clinical trials (N=2,397) are pelvic discomfort (6.0%), OHSS (4.3%, see also section 4.4), headache (4.0%), pelvic pain (2.9%), nausea (2.3%), fatigue (1.5%), and breast tenderness (1.3%). 
Najpogosteje poročani neželeni učinki med zdravljenjem z zdravilom Elonva v kliničnih preskušanjih (N = 2.397) so bili neugodje v medenici (6,0 %), OHSS (4,3 %, glejte tudi poglavje 4.4), glavobol (4,0 %), bolečine v medenici (2,9 %), slabost (2,3 %), utrujenost (1,5 %) in občutljivost dojk (1,3 %).
The GnRH antagonist is used to prevent premature Luteinising Hormone (LH) surges. 
Antagonist GnRH uporabimo za preprečevanje prezgodnjega zvišanja koncentracije luteinizirajočega hormona (LH).
The first symptoms of ovarian overstimulation may be noticed as pain in the stomach (abdomen), feeling sick or diarrhoea. 
Prvi simptomi hiperstimulacije jajčnikov so opazni v obliki bolečin v trebuhu (abdomnu) ter občutka slabosti ali driske.
The syringe is packed together with a sterile injection needle. 
Injekcijska brizga je pakirana skupaj s sterilno injekcijsko iglo.
Elonva may cause a false positive hCG pregnancy test if the test is administered during the ovarian stimulation portion of the ART cycle. 
Zdravilo Elonva lahko povzroči lažno pozitiven hCG test nosečnosti, če se test izvede med stimulacijo jajčnikov v ART ciklu.
If you forgot to inject Elonva on the day you should have, contact your doctor immediately. 
Če si pozabite injicirati zdravilo Elonva na predvideni dan, se takoj posvetujte z zdravnikom.
In case of inadvertent exposure to Elonva during pregnancy, clinical data are not sufficient to exclude an adverse outcome of pregnancy. 
V primeru, da je v času nosečnosti prišlo do nenamerne izpostavljenosti zdravilu Elonva, dosedanji klinični podatki niso zadostni, da bi lahko izključili neželeni izid nosečnosti.
Elonva contains the active ingredient corifollitropin alfa and belongs to the group of medicines called gonadotropic hormones. 
Zdravilo Elonva vsebuje učinkovino korifolitropin alfa in spada v skupino zdravil, imenovanih gonadotropni hormoni.
The European Medicines Agency has deferred the obligation to submit the results of studies with Elonva in one or more subsets of the paediatric population in hypogonadotrophic hypogonadism (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Elonva za vse skupine pediatrične populacije s hipogonadoptropnim hipogonadizmom (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Ovarian torsion may be related to other conditions, such as OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, and previous or current ovarian cysts. 
Torzija jajčnikov je lahko povezana z drugimi stanji, kot so OHSS, nosečnost, predhodne operacije trebuha, torzija jajčnikov v preteklosti in v preteklosti ali trenutno prisotne ciste jajčnikov.
(0.10-0.18 L/h 
0,10 do 0,18 l/h
In ART there is an increased risk of OHSS with 18 or more follicles of 11 mm or more in diameter. 
Pri asistirani reprodukciji obstaja povečano tveganje za OHSS pri 18 ali več foliklih premera 11 mm ali več.
What you need to know before you use Elonva 
Kaj morate vedeti, preden boste uporabili zdravilo Elonva
In animal studies reproductive toxicity has been observed (see preclinical safety data in section 5.3). 
V študijah pri živalih so opazili toksičnost oz. vpliv na sposobnost razmnoževanja (glejte predklinične podatke o varnosti v poglavju 5.3).
The daily dose of (rec)FSH may depend on the ovarian response. 
Dnevni odmerek (rek)FSH je lahko odvisen od odziva jajčnikov.
The long duration of FSH activity was achieved by adding the carboxy-terminal peptide of the β-subunit of human chorionic gonadotropin (hCG) to the β-chain of human FSH. 
Dolgo trajanje aktivnosti FSH je bilo doseženo z dodajanjem karboksi-terminalnega peptida β podenote humanega horionskega gonadotropina (hCG) β verigi humanega FSH.
OHSS is a medical event distinct from uncomplicated ovarian enlargement. 
OHSS je medicinski sopojav, ki se razlikuje od preprostega povečanja jajčnikov brez zapletov.
Ectopic pregnancy 
Ektopična nosečnost
Elonva is intended for single subcutaneous injection only. 
Zdravilo Elonva je namenjeno samo za enkratno subkutano injiciranje.
Intravascular thrombosis, which may originate in venous or arterial vessels, can result in reduced blood flow to vital organs or the extremities. 
Intravaskularna tromboza, ki se lahko začne v venski ali arterijski žili, lahko posledično povzroči zmanjšan krvni obtok v vitalnih organih ali okončinah.
Corifollitropin alfa is designed as a sustained follicle stimulant with the same pharmacodynamic profile as (rec)FSH, but with a markedly prolonged duration of FSH activity. 
Korifolitropin alfa je dolgotrajnejši stimulant rasti foliklov in ima enak farmakodinamični profil kot (rek)FSH, vendar znatno daljše trajanje aktivnosti FSH.
Your doctor may also check blood hormone levels. 
Lahko bo spremljal tudi koncentracije hormonov v krvi.
If you do a pregnancy test during your infertility treatment with Elonva, the test might wrongly suggest that you are pregnant. 
Če med zdravljenjem neplodnosti z zdravilom Elonva opravite test nosečnosti, lahko test napačno pokaže, da ste noseči.
The primary efficacy endpoint in the ENGAGE study was ongoing pregnancy (assessed at least 10 weeks after embryo transfer). 
Primarni opazovani dogodek učinkovitosti v študiji ENGAGE je bila potekajoča nosečnost (ocenjena vsaj 10 tednov po prenosu zarodka).
Exposure to corifollitropin alfa increases proportionally with dose within the range of 60 micrograms to 240 micrograms. 
Izpostavljenost korifolitropinu alfa se v razponu odmerkov od 60 do 240 mikrogramov povečuje sorazmerno odmerku.
It is not established whether or not treatment with gonadotropins increases the risk of these tumours in infertile women. 
Ni bilo ugotovljeno, ali zdravljenje z gonadotropini poveča tveganje za nastanek teh tumorjev pri neplodnih ženskah ali ne.
The number of oocytes retrieved was a key secondary efficacy endpoint. 
Število dobljenih jajčec je bil ključni sekundarni opazovani dogodek učinkovitosti.
In these women the benefits of gonadotropin administration need to be weighed against the risks. 
Pri teh ženskah je torej treba pretehtati koristi in tveganja uporabe gonadotropinov.
The woman and her partner should be advised of the potential risks for the mother (pregnancy and delivery complications) and the neonate (low birth weight) before starting treatment. 
Pred začetkom zdravljenja morate žensko in njenega partnerja torej obvestiti o potencialnih tveganjih za mater (zapleti med nosečnostjo in pri porodu) in novorojenčka (majhna porodna teža).
The eggs are collected from the ovary 34-36 hours later. 
Od 34 do 36 ur pozneje vam bo jajčeca odvzel iz jajčnikov.
The use of Elonva during pregnancy is not indicated. 
Uporaba zdravila Elonva med nosečnostjo ni indicirana.
(body weight greater than 60 kg and less than or equal to 90 kg) 
(telesna masa večja od 60 kg in manjša ali enaka 90 kg)
Elonva causes the growth and development of several follicles at the same time by a controlled stimulation of the ovaries. 
Zdravilo Elonva povzroča sočasno rast in zorenje več foliklov z nadzorovano stimulacijo jajčnikov.
The mean number of embryos transferred in the FTET cycles of ENGAGE was 1.7 in both treatment groups. 
Povprečno število prenešenih zarodkov v FTET ciklih študije ENGAGE je bilo v obeh skupinah 1,7.
Follow current clinical practice for reducing the risk of OHSS during Assisted Reproductive Technology (ART). 
Za zmanjšanje tveganja za nastanek OHSS med programom asistirane reprodukcije (ART) je treba slediti trenutni klinični praksi.
Therefore, your doctor should perform an early ultrasound examination to exclude the possibility of pregnancy outside the uterus. 
Zato mora zdravnik zgodaj opraviti ultrazvočno preiskavo, da bi izključil možnost zunajmaternične nosečnosti.
Women with known risk factors for a high ovarian response may be especially prone to the development of OHSS following treatment with Elonva. 
Ženske z znanimi dejavniki tveganja za močan odziv jajčnikov so lahko po zdravljenju z zdravilom Elonva še posebej nagnjene k nastanku OHSS.
Clear and colourless aqueous solution. 
bistra in brezbarvna vodna raztopina
To check the effects of treatment, your doctor will do ultrasound scans of your ovaries. 
Za preverjanje učinkovitosti zdravljenja bo zdravnik opravil ultrazvočni pregled jajčnikov.
OHSS causes fluid to build up suddenly in your stomach and chest areas and can cause blood clots to form. 
OHSS povzroči nenadno kopičenje tekočine v trebuhu in področju prsne votline in lahko povzroči nastanek krvnih strdkov.
(body weight greater than or equal to 50 kg) 
(telesna masa večja ali enaka 50 kg)
You may use Elonva only once during the same treatment cycle, otherwise, the chance of having OHSS may increase. 
Zdravilo Elonva lahko uporabite le enkrat v okviru istega ciklusa zdravljenja, ker se sicer poveča verjetnost za nastanek sindroma hiperstimulacije jajčnikov (OHSS).
What Elonva is and what it is used for What you need to know before you use Elonva How to use Elonva 
Kaj je zdravilo Elonva in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Elonva Kako uporabljati zdravilo Elonva Možni neželeni učinki
- Wash your hands with soap and water and dry them before you use Elonva. 
- Pred uporabo zdravila Elonva si roke umijte z milom in vodo in jih posušite.
Elonva 150 µg recFSH 300 IU N=268 N=128 N=756 N=750 N=694 N=696 
N = 268 N = 128 N = 756 N = 750 N = 694 N = 696
Mean number of oocytes Difference [95% CI] 
Povprečno število jajčec Razlika [95 % IZ]
If treatment with Elonva results in pregnancy, there is a higher chance of pregnancy outside the uterus (an ectopic pregnancy). 
Če zdravljenje z zdravilom Elonva vodi do zanositve, obstaja večja verjetnost za zunajmaternično nosečnost (t.i. ektopično nosečnost).
Before starting to use this medicine, tell your doctor if you have ever had ovarian hyperstimulation syndrome (OHSS). 
Preden začnete uporabljati to zdravilo, obvestite zdravnika, če ste imeli kadar koli v preteklosti sindrom hiperstimulacije jajčnikov (OHSS).
Elonva is indicated for Controlled Ovarian Stimulation (COS) in combination with a Gonadotropin Releasing Hormone (GnRH) antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. 
Zdravilo Elonva je indicirano za nadzorovano stimulacijo jajčnikov (COS) v kombinaciji z uporabo antagonista gonadotropin sproščujočega hormona (GnRH) za razvoj več foliklov pri ženskah v programu asistirane reprodukcije (ART).
There are limited data on the use of Elonva in combination with a GnRH agonist. 
Podatkov o uporabi zdravila Elonva v kombinaciji z agonistom GnRH je malo.
Women should be advised that if they feel dizzy, they should not drive or use machines. 
Ženskam svetujte, naj v primeru omotičnosti ne vozijo in ne upravljajo strojev.
Elonva should be administered as a single subcutaneous injection, preferably in the abdominal wall, during the early follicular phase of the menstrual cycle. 
Zdravilo Elonva dajte bolnici v obliki enkratne subkutane injekcije, najbolje v trebušno steno, in sicer med zgodnjo folikularno fazo menstrualnega ciklusa.
Although data in hepatically impaired patients are not available, hepatic impairment is unlikely to affect the pharmacokinetic profile of corifollitropin alfa. 
Čeprav ni podatkov za bolnice z okvaro jeter, je malo verjetno, da bi okvara jeter vplivala na farmakokinetični profil korifolitropina alfa.
Blood clots can cause serious medical conditions, such as: - blockage in your lungs (pulmonary embolus) - stroke - heart attack - blood vessel problems (thrombophlebitis) - a lack of blood flow (deep venous thrombosis) that may result in a loss of your arm or leg. 
Krvni strdki lahko povzročijo hude bolezni, kot so: - zapora v pljučih (pljučna embolija), - možganska kap, - srčni infarkt, - težave s krvnimi žilami (tromboflebitis), - zmanjšanje krvnega pretoka (globoka venska tromboza), kar lahko vodi do izgube roke ali noge.
As soon as three follicles  17 mm are observed, a single injection of 5,000 up to 10,000 IU hCG is administered the same day or the day thereafter to induce final oocyte maturation. 
Kakor hitro opazite tri folikle premera  17 mm, dajte bolnici eno injekcijo od 5.000 do 10.000 i.e. hCG isti dan ali naslednji dan, da boste sprožili dokončno zorenje jajčeca.
Elonva must be injected under the skin (subcutaneously) into a skin fold (that you pinch between your thumb and index finger), preferably just below the navel. 
Zdravilo Elonva je treba vedno injicirati pod kožo (subkutano), in sicer v kožno gubo (ki jo primete s palcem in kazalcem), po možnosti tik pod popkom.
Seven days after the injection with Elonva on stimulation day 1, COS treatment may be continued with daily injections of (recombinant) Follicle Stimulating Hormone [(rec)FSH] until the criterion for triggering final oocyte maturation (3 follicles ≥ 17 mm) has been reached. 
Sedem dni po injiciranju zdravila Elonva na 1. dan stimulacije lahko zdravljenje COS nadaljujete z vsakodnevnimi injekcijami (rekombinantnega) folikle stimulirajočega hormona [(rek)FSH], dokler ne bodo izpolnjeni kriteriji za sprožitev dokončnega zorenja jajčeca (3 folikli ≥ 17 mm).
*Adverse reactions were identified through post-marketing surveillance. 
* Neželene učinke so opazili v času trženja zdravila.
Elonva is indicated for use in infertility (see section 4.1). 
Zdravilo Elonva je indicirano za uporabo pri neplodnosti (glejte poglavje 4.1).
Do not inject Elonva into a muscle. 
Zdravila Elonva si ne smete injicirati v mišico.
- Clean about 5 cm around the point where the needle will go in and let the disinfectant dry for at least one minute before proceeding. 
- Očistite približno 5 cm okoli mesta vboda in počakajte vsaj eno minuto preden nadaljujete, da se razkužilo posuši.
Storage by the pharmacist Store in a refrigerator (2ºC-8°C). 
Shranjevanje v lekarni Shranjujte v hladilniku (2 °C - 8 °C).
Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Water for injections 
natrijev hidroksid (za uravnavanje pH) klorovodikova kislina (za uravnavanje pH) voda za injekcije
FTET Cycles of PURSUE 
FTET cikli študije PURSUE
Seven days after the injection of Elonva, your doctor may decide to continue your stimulation cycle with another gonadotropic hormone, like (rec)FSH. 
Sedem dni po injekciji zdravila Elonva se bo zdravnik lahko odločil, da nadaljuje cikel stimulacije z drugim gonadotropnim hormonom, na primer (rek)FSH.
The syringe is equipped with an automatic safety system to prevent needle stick injuries after use and is packed together with a sterile injection needle. 
Injekcijske brizge so opremljene z avtomatskim varnostnim sistemom, ki preprečuje poškodbe zaradi vboda igle po končani uporabi, in so pakirane skupaj s sterilno injekcijsko iglo.
- Swab the injection site (the area just below your belly button) with a disinfectant (for example, alcohol) to remove any surface bacteria. 
- Mesto vboda (področje tik pod popkom) razkužite z razkužilom (npr. z alkoholom), da odstranite bakterije na površini.